---
input_text: Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis
  type I. Lysosomal enzyme deficiencies comprise a large group of genetic disorders
  that generally lack effective treatments. A potential treatment approach is to engineer
  the patient's own hematopoietic system to express high levels of the deficient enzyme,
  thereby correcting the biochemical defect and halting disease progression. Here,
  we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets
  the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic
  stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels,
  maintain long-term repopulation and multi-lineage differentiation potential, and
  can improve biochemical and phenotypic abnormalities in an immunocompromised mouse
  model of Mucopolysaccharidosis type I. These studies provide support for the development
  of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment
  for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible
  platform for the expression of lysosomal enzymes making it applicable to other lysosomal
  storage disorders.
raw_completion_output: |-
  primary_disease: Mucopolysaccharidosis type I
  medical_actions: Ex vivo genome editing using CRISPR-Cas9; Targeting the lysosomal enzyme iduronidase to the CCR5 safe harbor locus; Modifying human CD34+ hematopoietic stem and progenitor cells
  symptoms: Biochemical and phenotypic abnormalities
  chemicals: CRISPR-Cas9; Iduronidase
  action_annotation_relationships: Ex vivo genome editing using CRISPR-Cas9 TREATS biochemical and phenotypic abnormalities IN Mucopolysaccharidosis type I; Targeting the lysosomal enzyme iduronidase to the CCR5 safe harbor locus TREATS biochemical and phenotypic abnormalities IN Mucopolysaccharidosis type I; Modifying human CD34+ hematopoietic stem and progenitor cells TREATS biochemical and phenotypic abnormalities IN Mucopolysaccharidosis type I
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Modifying human CD34+ hematopoietic stem and progenitor cells TREATS biochemical and phenotypic abnormalities IN Mucopolysaccharidosis type I

  ===

extracted_object:
  primary_disease: MONDO:0001586
  medical_actions:
    - Ex vivo genome editing using CRISPR-Cas9
    - Targeting the lysosomal enzyme iduronidase to the CCR5 safe harbor locus
    - Modifying human CD34+ hematopoietic stem and progenitor cells
  symptoms:
    - Biochemical and phenotypic abnormalities
  chemicals:
    - CRISPR-Cas9
    - Iduronidase
  action_annotation_relationships:
    - subject: Ex vivo genome editing
      predicate: TREATS
      object: biochemical and phenotypic abnormalities
      qualifier: MONDO:0001586
      subject_extension: CRISPR-Cas9
    - subject: Targeting the lysosomal enzyme iduronidase to the CCR5 safe harbor
        locus
      predicate: TREATS
      object: biochemical and phenotypic abnormalities
      qualifier: MONDO:0001586
      subject_extension: lysosomal enzyme iduronidase
    - subject: Modifying
      predicate: TREATS
      object: biochemical and phenotypic abnormalities
      qualifier: MONDO:0001586
      subject_extension: human CD34+ hematopoietic stem and progenitor cells
named_entities:
  - id: MONDO:0001586
    label: mucopolysaccharidosis type I
  - id: MONDO:1012617
    label: Mucopolysaccharidosis Type I (MPS I)
  - id: CHEBI:60285
    label: DOPE
  - id: MAXO:0001521
    label: nasal administration
  - id: MONDO:0011758
    label: Mucopolysaccharidosis type I Hurler (MPSIH)
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000487
    label: clinical assessment (growth measurement, kyphosis and genu velgum evaluation)
  - id: HP:0002808
    label: kyphosis
  - id: HP:0001376
    label: limited joint mobility
  - id: HP:0008807
    label: acetabular dysplasia
  - id: MAXO:0010034
    label: Corneal transplantation
  - id: HP:0007957
    label: Corneal clouding
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000526
    label: clinical examination
  - id: CHEBI:143889
    label: glycosaminoglycan (GAG)
  - id: HP:0004322
    label: short stature
  - id: HP:0005619
    label: thoracolumbar kyphosis
  - id: HP:0000943
    label: dysostosis multiplex
  - id: MONDO:0011759
    label: Hurler-Scheie syndrome
  - id: HP:0001387
    label: joint stiffness
  - id: HP:0000403
    label: recurrent otitis media
  - id: HP:0001999
    label: facial dysmorphism
  - id: HP:0002781
    label: Upper airway obstruction
  - id: HP:0001638
    label: Cardiomyopathy
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:58187
    label: Alginate
  - id: CHEBI:53412
    label: PLL (Poly-L-lysine)
  - id: CHEBI:50594
    label: Carbon nanotubes
  - id: HP:0007663
    label: Reduced visual acuity
  - id: MAXO:0000016
    label: cellular therapy
  - id: CHEBI:19226
    label: Tm
  - id: MONDO:0017385
    label: mucopolysaccharidosis type I (MPSI) Hurler
  - id: MAXO:0000018
    label: Biomarker assessment
  - id: HP:0001138
    label: Optic neuropathy
  - id: HP:0000488
    label: Retinopathy
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:33310
    label: MCT (NE)
  - id: HP:0001367
    label: joint disease
  - id: HP:0002652
    label: skeletal dysplasia
  - id: HP:0000618
    label: vision impairments
  - id: HP:0000365
    label: hearing impairments
  - id: MONDO:0007147
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: MAXO:0000915
    label: Overnight polysomnography (PSG)
  - id: HP:0002104
    label: Apnea
  - id: HP:0040213
    label: Hypopnea
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0009290
    label: Pompe Disease
